Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Onyx To Buy Proteolix
by Marc S. Reisch
October 19, 2009
| A version of this story appeared in
Volume 87, Issue 42
Onyx Pharmaceuticals has signed a definitive agreement to acquire South San Francisco-based biopharmaceutical firm Proteolix for $276 million in cash. The acquisition would extend Onyx' current franchise in the treatment of liver and kidney cancer to the treatment of hematological malignancies. Proteolix' lead compound, carfilzomib, is a small-molecule proteasome inhibitor now in clinical trials to treat patients with multiple myeloma. The blood disease affects more than 180,000 people worldwide. Onyx, based in Emeryville, Calif., now sells Nexavar, a multiple kinase inhibitor to treat liver and kidney cancer, in partnership with Bayer HealthCare.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter